What most patients actually pay

For most patients presenting with a single focal cartilage defect, the relevant figure is £3,000 — not the headline maximum. The majority of straightforward presentations require only one box of ChondroFiller, and that single-box price is the complete, all-inclusive cost: initial consultation, pre-procedure imaging review, real-time ultrasound-guided injection, IV antibiotic cover, and a six-week follow-up appointment are all covered. There are no day-of additions or separately billed components under the published pricing model.

The box count — and therefore the exact price tier — is settled at a pre-procedure imaging review before the appointment is booked. Patients do not arrive at the clinic still uncertain about what they will pay; the total cost is confirmed in advance.

The full tiered structure runs from £3,000 (one box) through £5,500 (two boxes) to £8,000 (three boxes), with the number of boxes driven by the size and complexity of the defect rather than by which joint is being treated. Larger or multi-compartment presentations, and more complex clinical pathways, are discussed in the sections below — but for a standard single-defect knee assessment, the one-box price is where most patients land.

The three-tier pricing structure explained

Three fixed price points cover the full range — and the step between each is consistent:

• One box — £3,000
• Two boxes — £5,500
• Three boxes — £8,000

Each additional box adds £2,500. Notably, the same tariff applies regardless of which joint is being treated: knee, hip, shoulder, ankle, elbow, wrist, foot, and hand all sit within the same structure. Joint location does not change the tier — only box count does.

What moves a patient between tiers

The imaging review does more than confirm candidacy; it determines the volume of collagen scaffold required to fill the defect space adequately. A single contained lesion typically calls for one box. Larger defects, multiple lesions within the same joint, or presentations spanning more than one compartment are more likely to require two or three. Because the scaffold needs sufficient volume to gel in situ and form a stable matrix, the quantity is a clinical determination — it reflects what the imaging shows rather than any commercial consideration.

Comparing quotes

The published tiers are all-inclusive (as set out in the previous section) rather than procedure-only fees. Patients sourcing quotes from any specialist offering this pathway should confirm explicitly whether intravenous antibiotic cover and the six-week follow-up are included, since itemised pricing models do exist and a lower headline figure may not represent an equivalent scope of care.

Larger joints and combination protocols

Beyond the standard three-tier structure, two higher-cost pathways apply to specific clinical presentations.

For larger or multi-compartment joints — particularly the hip and shoulder — published sources cite an approximate range of £6,500–£9,500. This figure is a guide, not a fixed tariff: it rests on fewer independently confirmed data points than the standard knee tiers, and patients considering treatment for a large joint should treat it as an indicative band and confirm the precise cost at their pre-procedure imaging review.

The CFI++ combination protocol

At the upper end sits the CFI++ pathway — ChondroFiller combined with mesenchymal stem cells (MSC) and Arthrosamid — priced from £10,500. This protocol targets severe or bone-on-bone joint wear as a potential alternative to joint replacement, and is not a typical first-line presentation.

The two injectable components within CFI++ are distinct and should not be conflated. ChondroFiller is the regenerative scaffold: an acellular collagen matrix that gels in situ and recruits the patient's own progenitor cells through acellular matrix-induced chondrogenesis. Arthrosamid is a polyacrylamide hydrogel — a non-regenerative cushioning agent that acts through an entirely different mechanism. Including both in a combination protocol does not make them equivalent; their roles in the joint are separate.

Neither the large-joint range nor the CFI++ pathway represents the typical patient experience — both are reserved for presentations that fall outside the standard single-defect assessment.

Why ChondroFiller costs more than standard injections

The price gap between ChondroFiller and a standard hyaluronic acid or corticosteroid injection is not a mark-up on a commoditised product — it reflects the regulatory category and supply pathway of the device itself.

ChondroFiller holds Class III CE-marked status under European medical-device regulation. Class III is the highest-risk category: it covers devices that sustain or restore a vital function, and includes implantable cardiac devices. The classification triggers a more demanding conformity-assessment route than the Class II or Class IIa status that most viscosupplementation products carry, and that assessment cost is embedded in the product price.

The device is also manufactured by Meidrix Biomedicals GmbH in Germany and imported to the UK under prescription — an additional regulatory and logistics layer absent from domestically stocked injectables.

By contrast, hyaluronic acid and corticosteroid injections serve different purposes: viscosupplementation and short-term symptom control respectively, rather than a regenerative scaffold pathway. Neither is an inferior option in absolute terms; they address different clinical questions. The cost difference does not make ChondroFiller the right choice for every patient — it reflects what the device is, not a premium applied arbitrarily over cheaper alternatives.

NHS funding, private insurance, and self-pay

ChondroFiller sits outside NHS provision — there is no established funding route through the health service, and the default patient pathway is self-pay.

Private medical insurance does not cover it as a matter of routine. Bupa and AXA do not include ChondroFiller under their standard benefit schedules. The picture is, however, more nuanced than a blanket refusal: the procedure carries two recognised CCSD billing codes — W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy) — and as of late 2025, case-by-case approvals had been reported with Bupa, Aviva, and WPA. Patients with policies from any of these insurers are worth encouraging to submit a formal written pre-authorisation request before ruling coverage out entirely.

Pre-authorisation is not guaranteed, and outcomes vary between policies and individual clinical circumstances. Because this area of insurance practice continues to develop, confirming the current position directly with the insurer — rather than relying on a clinic FAQ — is the more reliable approach.

On financing, instalment and patient-finance options are rarely advertised publicly by providers; patients should ask the treating clinic directly whether a payment plan is available, as terms differ between services.

The self-pay status is a reflection of where the procedure sits in the regulatory and commissioning landscape, not of its clinical credibility — a point addressed in the section above on device classification.

Finding a UK specialist who offers ChondroFiller

Cross-provider price comparison is genuinely limited at present — comparable injection-pathway pricing from other UK providers is not widely published, so patients cannot easily benchmark one clinic against another before an initial consultation.

When contacting any specialist, three questions are worth asking before booking:

• What is included in the quoted price? Confirm that the consultation, pre-procedure imaging review, the ultrasound-guided injection, IV antibiotic cover, and the six-week follow-up are all bundled — not billed separately.
• How many boxes are likely to be needed? The box count drives the price tier; a specialist can estimate this accurately only after reviewing your imaging.
• Can the clinic assist with insurer correspondence? If you hold a policy with Bupa, Aviva, or WPA, ask whether the clinic supports pre-authorisation requests — the procedure carries recognised billing codes, as discussed in the previous section.

Because the number of UK clinics offering ChondroFiller as an outpatient injection remains small, establishing which specialists cover your region is the practical first step — cross-country availability matters more here than it does for common injection therapies. Search MSK lists specialists across the UK who offer ChondroFiller injection; filtering by region and specialty will show which clinicians are available near you. Wherever you book, expect a pre-procedure imaging review before a final price is confirmed — that step is standard, and it is the point at which box count and total cost are fixed.